Acute nonlymphocytic leukemia after treatment of small cell lung cancer

David H. Johnson, Lester L. Porter, Alan F. List, Kenneth R. Hande, John D. Hainsworth, F. Anthony Greco

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


From 1977 to 1982, 377 patients with small cell lung cancer were treated at Vanderbilt University Medical Center. All patients received combination chemotherapy consisting of cyclophosphamide, doxorubicin, and vincristine (CAV) with or without methotrexate, etoposide, and/or hexamethylmelamine. Thoracic and/or prophylactic cranial irradiation was administered to 159 (42 percent) and 192 (51 percent) patients, respectively. Acute nonlymphocytic leukemia was observed in two patients at 22 and 81 months from the start of therapy. The relative risk of leukemia was 154 (95 percent confidence limit, 38 to 293). A Kaplan-Meier estimate of the cumulative probability of leukemia was 1.9 ± 1.4 percent seven years after the start of treatment. The relative risk of leukemia is significantly increased in this group of patients (p <0.0001). Acute nonlymphocytic leukemia is a long-term complication of small cell lung cancer therapy.

Original languageEnglish (US)
Pages (from-to)962-968
Number of pages7
JournalThe American Journal of Medicine
Issue number6
StatePublished - Dec 1986

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Acute nonlymphocytic leukemia after treatment of small cell lung cancer'. Together they form a unique fingerprint.

Cite this